Noven will pocket the second of three potential $25 million milestones outlined in its deal with Shire. Shire says that the ADHD drug Daytrana continues to rack up enough market share to trigger the payments, exceeding $50 million in revenue for the 12 months ended on June 30. Noven will get its third big milestone payment if Daytrana breaks the $75 million mark.
- check out the release
- here's the report from Tech Journal South
Noven expands pipeline with $125M JDS buyout. Report
FDA rejects Noven's copycat version of Duragesic pain patch. Report
FDA approves Daytrana ADHD patch. Report